Why the study?
Bleeding events related to standard 12-month DAPT after ACS and PCI prompted the evaluation of strategies to mitigate bleeding risk, such as early ASA discontinuation with P2Y12 receptor antagonist monotherapy.
Does early discontinuation of acetylsalicylic acid reduce bleeding risk in patients with acute coronary syndrome undergoing percutaneous coronary interventions?
Does early discontinuation of acetylsalicylic acid reduce bleeding risk in patients with acute coronary syndrome undergoing percutaneous coronary interventions?
Early discontinuation of aspirin after 1-3 months of DAPT in ACS patients undergoing PCI reduces bleeding risk while maintaining ischemic protection.
Early ticagrelor monotherapy after short DAPT may lower bleeding in ACS post-PCI; leaves open optimal duration and high-risk subgroup effects.
Early percutaneous coronary intervention (PCI) and long-term aggressive antithrombotic treatment based on dual antiplatelet therapy (DAPT) are the most important elements in the treatment of patients with acute coronary syndrome (ACS). The most studied and recommended for ACS is the 12-month DAPT (combination of acetylsalicylic acid (ASA) and P2Y 12 receptor antagonist). Bleeding events due to DAPT after ACS and after PCI forced the search for approaches aimed at reducing the risk of such complications, especially noticeable when using a powerful blocker of the P2Y 12 receptor of platelets. One of the recently identified solutions turned out to be early (1-3 months after the therapy initiation) discontinuation of ASA with continued administration of one antiplatelet agent (P2Y 12 receptor antagonist). The article provides arguments in favor of this approach.
No takes yet. Share an insight, caveat, or question.
О. В. Аверков (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: